Awarded contract

NHS National Generic Pharmaceuticals Wave 13

Details

Supplier(s)
Value
£192
Topic
Pharmaceutical products
Published
14 January 2022

Tender description

Potential periods of call-offs under the framework agreement:<br/><br/>Transition (Everolimus)<br/>CESW: 1 March 2022 – 30 September 2023 (19 months)<br/>LSNE: 1 March 2022 – 31 January 2023 (11 months)<br/>NWLN: 1 March 2022 – 31 January 2023 (11 months)<br/><br/>Oral Products plus non-parenterals<br/>All Regions: 1 March 2022 - 31 May 2024 (27 months)<br/><br/>Hospital Only Products<br/>CESW: 1 February 2022 – 30 September 2023 (20 months)<br/>LSNE: 1 February 2022 – 31 May 2024 (28 months)<br/>NWLN: 1 February 2022 – 31 January 2023 (12 months) Lot 1: Lot 1 - CM/PHG/17/5532/00 Transition (Everolimus) Invitation to offer for NHS National Generic Pharmaceuticals Wave 13<br/>Offer reference number: CM/PHG/17/5532<br/>Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority’s sole discretion) for a period or periods up to a total of 48 months.<br/><br/>Potential periods of call-offs under the framework agreement:<br/><br/>Transition (Everolimus)<br/>CESW: 1 March 2022 – 30 September 2023 (19 months)<br/>LSNE: 1 March 2022 – 31 January 2023 (11 months)<br/>NWLN: 1 March 2022 – 31 January 2023 (11 months)<br/><br/>Oral Products plus non-parenterals<br/>All Regions: 1 March 2022 - 31 May 2024 (27 months)<br/><br/>Hospital Only Products<br/>CESW: 1 February 2022 – 30 September 2023 (20 months)<br/>LSNE: 1 February 2022 – 31 May 2024 (28 months)<br/>NWLN: 1 February 2022 – 31 January 2023 (12 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 2: Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals Invitation to offer for NHS National Generic Pharmaceuticals Wave 13<br/>Offer reference number: CM/PHG/17/5532<br/>Period of framework agreement:The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority’s sole discretion) for a period or periods up to a total of 48 months.<br/><br/>Potential periods of call-offs under the framework agreement:<br/><br/>Transition (Everolimus)<br/>CESW: 1 March 2022 – 30 September 2023 (19 months)<br/>LSNE: 1 March 2022 – 31 January 2023 (11 months)<br/>NWLN: 1 March 2022 – 31 January 2023 (11 months)<br/><br/>Oral Products plus non-parenterals<br/>All Regions: 1 March 2022 - 31 May 2024 (27 months)<br/><br/>Hospital Only Products<br/>CESW: 1 February 2022 – 30 September 2023 (20 months)<br/>LSNE: 1 February 2022 – 31 May 2024 (28 months)<br/>NWLN: 1 February 2022 – 31 January 2023 (12 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 3: Lot 3 - CM/PHG/17/5532/02 Hospital Only Products Invitation to offer for NHS National Generic Pharmaceuticals Wave 13<br/>Offer reference number: CM/PHG/17/5532<br/>Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority’s sole discretion) for a period or periods up to a total of 48 months.<br/><br/>Potential periods of call-offs under the framework agreement:<br/><br/>Transition (Everolimus)<br/>CESW: 1 March 2022 – 30 September 2023 (19 months)<br/>LSNE: 1 March 2022 – 31 January 2023 (11 months)<br/>NWLN: 1 March 2022 – 31 January 2023 (11 months)<br/><br/>Oral Products plus non-parenterals<br/>All Regions: 1 March 2022 - 31 May 2024 (27 months)<br/><br/>Hospital Only Products<br/>CESW: 1 February 2022 – 30 September 2023 (20 months)<br/>LSNE: 1 February 2022 – 31 May 2024 (28 months)<br/>NWLN: 1 February 2022 – 31 January 2023 (12 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Timeline

  1. Completed: Award date30 November 2021
  2. Completed: Award published14 January 2022
    Current notice

About the buyer

NHS England is a public sector buyer in United Kingdom publishing tenders and awards on Stotles. Explore their procurement activity and find more opportunities like this one.

Relevant CPV codes

  • 33600000 · Pharmaceutical products

AI insights

  • Is there a preferred supplier?
  • What are the buyers pain points?
  • What has the buyer previously procured?
  • What are the key requirements?
Sign-up to enrich

Decision makers

Connect with the people behind this procurement.

Contact nameJob titlePhone numberWork email
Head of Procurement+44 •••• ••••••
Commercial Director+44 •••• ••••••
Procurement Manager+44 •••• ••••••
Category Lead+44 •••• ••••••
Senior Buyer+44 •••• ••••••
Contracts Manager+44 •••• ••••••

6 similar open tenders

See more open tenders related to NHS National Generic Pharmaceuticals Wave 13.

Explore all open tenders

Win more public sector contracts

Track every UK and Ireland tender in one place — set up alerts, find decision-makers, and never miss an opportunity.